Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03774758

Biomarkers for Risk Stratification in Lung Cancer

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.

Official title: Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

OBSERVATIONAL

Enrollment

590

Start Date

2017-12-17

Completion Date

2025-12-31

Last Updated

2025-03-20

Healthy Volunteers

Not specified

Interventions

DIAGNOSTIC_TEST

Guardant Health ct-DNA LUNAR assay

Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.

Locations (3)

Zuckerberg San Francisco General Hospital and Trauma Center

San Francisco, California, United States

San Francisco VA Medical Center

San Francisco, California, United States

University of California, San Francisco

San Francisco, California, United States